Aardvark gets FDA alignment to lower Phase 3 PWS trial min age to 10

Aardvark Therapeutics, Inc.

FDA aligned on protocol amendment for Phase 3 HERO trial of ARD-101, lowering minimum age from 13 to 10 years old.
Expansion broadens patient population in Prader-Willi Syndrome; topline data readout expected in Q3 2026.
CEO cites community support and historical data suggesting younger patients benefit from early intervention.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.